Burimamide

Burimamide

Burimamide
Skeletal formula
Space-filling model
Identifiers
CAS number  YesY
PubChem
ChemSpider  YesY
UNII  YesY
KEGG  YesY
ChEMBL  YesY
Jmol-3D images Image 1
Properties
Molecular formula C9H16N4S
Molar mass 212.32 g/mol
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 YesY   YesY/N?)

Burimamide is an antagonist at the H2 and H3 histamine receptors. It is largely inactive as an H2 antagonist at physiological pH,[1] but its H3 affinity is 100x higher. It is a thiourea derivative.

Burimamide was first developed by scientists at Smith, Kline & French (SK&F; now GlaxoSmithKline) in their intent to develop a histamine antagonist for the treatment of peptic ulcers.[2] The discovery of buriamide ultimately led to the development of cimetidine (Tagamet).[2]

See also

References

  1. ^  
  2. ^ a b -receptor Antagonists"2: Discovery of Histamine H®"Tagamet. National Historic Chemical Landmarks. American Chemical Society. Retrieved June 25, 2012.